06
Nov
Mumbai (Maharashtra) [India], November 6: Fredun Pharmaceuticals Limited (BSE – FREDUN | 539730), one of India’s leading pharmaceutical formulation manufacturing companies, has announced its unaudited financial results for Q2 & H1 FY27. The Company offers a diversified portfolio spanning generics, cosmeceuticals, nutraceuticals, mobility solutions, and animal healthcare products. Key Financial Highlights Standalone key Financial Highlights – Q2 FY27 Total Income rose 84.21% YoY to ₹267.64 Cr from ₹145.29 Cr. EBITDA rose 90.74% YoY to ₹42.60 Cr from ₹22.34 Cr. EBITDA Margin improved 55 bps YoY to 15.92% from 15.37%. Net Profit rose 93.44% YoY to ₹18.83 Cr from ₹9.73 Cr.…
